TRAIL1 (ClinicalTrials.gov Identifier: NCT02808871) was a phase 2 randomised, double blind, placebo-controlled trial investigating pirfenidone in rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We were delighted to speak to Professor Ivan O. Rosas (Baylor College of Medicine, Baylor Medicine McNair Campus, Houston, TX, USA) around the aims, design and inclusion criteria of the TRAIL1 study and the safety, tolerability and efficacy findings and what these mean for the treatment paradigm for RA-ILD.
The abstract ‘Randomized, Double Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease.‘ (Abstract number: RCT2886) was presented at ERS 2022, 4–6 September, 2022.
Questions
- What is the rationale for the use of pirfenidone in the treatment of RA-ILD? (0:52)
- What were the aims, design and inclusion criteria of the TRAIL1 study? (3:33)
- What were the primary and secondary endpoints of the study and how well were they achieved? (5:08)
- What is the clinical significance of these findings? (7:50)
Disclosures: Ivan O. Rosas discloses consulting for Genentech/Roche and receiving grant/ research support from Genentech/Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
For further information, please view the published study article here and the design article here.
